INTRODUCTION
Rickettsioses are a group of diseases that conventionally include rickettsial diseases, ehrlichiosis, analplasmosis, scrub typhus (caused by Orientia tsutsugamushi), and Q fever (caused by Coxiella burnetii), although the genera Ehrlichia, Anaplasma, Orientia, and Coxiella have been removed from the genus Rickettsia.1 They are common zoonoses in humans that may be the cause of fever of unknown origin in many clinical settings.2 Definitive diagnosis is made through the isolation or detection of the causative pathogens from specimens of the infected hosts, but these methods are laborious and isolating organisms from clinical specimen is difficult.3,4 Because of these disadvantages, serologic assessments that detect the specific antibodies against the organisms in sera have become the universally approved diagnostic methods for rickettsioses. However, serologic assessments are only available in research laboratories, not universally in general hospitals, and require paired serum to confirm the diagnosis, which often takes more than two weeks after the disease onset. Thus, clinicians often empirically administer antibiotics that are effective against rickettsioses, especially tetracyclines, before the final results of confirmatory tests are available.
In Taiwan, acute Q fever, scrub typhus, and murine typhus are the most common rickettsioses.5–9 Although the pathogens, vectors, and transmission routes of the three diseases are different, it is difficult to differentiate from each other by clinical manifestations and doxycycline is the recommended antibiotic for them. Clinicians often empirically prescribe doxycycline as preemptive treatment of patients who are highly suspected of acute Q fever, scrub typhus, or murine typhus, and defervescence is often achieved within 3 days. Because the response to doxycycline is so dramatic, it would make the diagnosis of these diseases unlikely if fever persisted for more than 3 days after treatment. Thus, the emergence of cases with delayed defervescence (fever > 3 days) after treatment with doxycycline will distract clinicians, including infectious disease specialists. This study was conducted to identify the clinical characteristics of acute Q fever, scrub typhus, and murine typhus with delayed defervescence despite doxycycline treatment.
MATERIALS AND METHODS
Identification of cases of acute Q fever, scrub typhus, and murine typhus.
Patients clinically suspected as cases of rickettsioses were initially reported to the department of infection control of E-Da Hospital by the clinicians. Because acute Q fever, scrub typhus, and murine typhus were the most common rickettsioses in Taiwan, and they were often difficult to be distinguished from each other in clinical, all three diseases were prospectively reported to and paired sera (acute and convalescent phase) were collected and sent to the Centers for Disease Control, Taipei, Taiwan (Taiwan CDC) simultaneously for confirming the diagnoses regardless of which disease was suspected. Serologic assessments for the presence of specific antibodies to C. burnetii, O. tsutsugamushi, and Rickettsia typhi were performed using an indirect immunofluorescence antibody assay (IFA) as previously described.6,8,9
Acute Q fever was diagnosed by either a titer of anti-phase II antigen IgG > 1:200 and anti-phase II antigen IgM > 1:80 in a single serum, or a 4-fold or greater rise of anti-phase II antigen IgG in paired sera. Scrub typhus was diagnosed by either an antibody titer of IgM > 1:80 for Karp, Kato, and Gilliam strains of O. tsutsugamushi, or a 4-fold or greater rise of total antibody titer in paired sera. Murine typhus was diagnosed by either a single IgM titer against R. typhi > 1:80 or a 4-fold or greater rise of IgG titers in paired sera.
Identification of studied cases.
The charts of the serologically confirmed cases of acute Q fever, scrub typhus, and murine typhus were reviewed and the demographic data, clinical manifestations, results of laboratory and imaging studies, administration of antibiotics, and highest daily body temperature were recorded for analysis. The dosage of doxycycline was 200 mg orally per day divided into two doses. For clinical practice, ear temperature was used to measure body temperature. The date of defervescence was defined as the first day of the highest body temperature lower than 37.5°C for more than 3 consecutive days. Antipyretics were used only when the body temperature was greater than 38.5°C. Delayed defervescence was defined as the number of days from the administration of doxycycline to defervescence > 3 days.
Patients with the following criteria were excluded from the study: 1) patients who had spontaneous remission defined as defervescence achieved without or before doxycycline treatment; 2) patients without delayed defervescence who received fluoroquinolone treatment within 3 days before the date of defervescence; 3) patients without available daily body temperatures resulting from treatment at the out-patient or emergency departments.
The patients were divided into two groups based on responses to doxycycline treatment: the delayed defervescence group and the group without delayed defervescence.
Confirming tests for hepatitis virus B (HBV) or C (HCV) infection.
Because elevated liver enzymes were found in a majority of cases of acute Q fever, scrub typhus, murine typhus, and HBV and HCV infections were endemic in Taiwan; confirming tests for HBV and HCV infection were performed. HBV infection was defined as the presence of hepatitis B surface antigen in serum detected by IMx HBsAg (V2) assay (Abbott IMx system). HCV infection was defined as the presence of antibody to hepatitis C virus in serum detected by IMx HCV version 3.0 (Abbott IMx system).
Statistical analysis.
Categorical variables were analyzed using χ2 or Fisher’s exact test where appropriate. Continuous variables were analyzed using the Student’s t test, whereas multivariate analysis was performed using logistic regression. All P values were two-tailed and a value < 0.05 was considered statistically significant. The results were analyzed using a commercially available software package (SPSS, version 12.0, Chicago, IL).
RESULTS
From April 2004 to December 2007, a total of 130 cases (80 acute Q fever, 40 scrub typhus, and 10 murine typhus) were confirmed by serologic tests at the E-Da Hospital. Among them, 24 (18.5%) were excluded, including 7 (5.4%) cases of spontaneous remission, 3 (2.3%) who received fluoroquinolones treatment within 3 days before defervescence, and 14 (10.8%) unavailable daily body temperatures. A total of 106 cases (61 acute Q fever, 38 scrub typhus, and 7 murine typhus) were included for analysis. Among them, 18 (17.0%) cases (9 acute Q fever, 7 scrub typhus, and 2 murine typhus) had delayed defervescence and 88 (83.0%) cases (52 acute Q fever, 31 scrub typhus, and 5 murine typhus) did not have delayed defervescence. The percentage of each disease in the two groups is not statistically different (Table 1). The percentage of fever in patients with and without delayed defervescence after doxycycline treatment is shown in Figure 1. The 33.3% (6/18) and 20.5% (18/88) patients with and without delayed defervescence, respectively, had combined other antibiotics (P = 0.233) (data not shown). Except for two patients with delayed defervescence who received additional fluoquinolones on the 5th and 7th day after doxycycline treatment, most of the combined antibiotics were beta-lactams and aminoglycosides, which were not effective for Q fever, scrub typhus, and murine typhus. Furthermore, steroid was administered in two patients with delayed defervescence on the 5th and 7th day after doxycycline treatment.
The demographic data and clinical symptoms and signs of cases are listed in Table 1. By univariate analysis, absence of headache (38.9% versus 9.1%, P = 0.004), jaundice (27.8% versus 8.0%, P = 0.030), icteric sclera (27.8% versus 8.0%, P = 0.030), and relative bradycardia (83.3% versus 44.3%, P = 0.003) were the predominant characteristics of those with delayed defervescence. Table 2 shows the results of laboratory examinations and image findings of cases. Only pulmonary involvement on chest x-ray (CXR) (55.6% versus 28.7%, P = 0.028) was predominant for cases with delayed defervescence. The duration from disease onset to doxycycline treatment is shown in Table 3 and no difference between the two groups was found.
Among the significant characteristics identified by univariate analysis, absence of headache (odds ratio [OR] = 8.310; 95% confidence interval [CI] = 1.990–34.706, P = 0.004), jaundice (OR = 6.242; 95% CI = 1.374–28.365, P = 0.018), and relative bradycardia (OR = 10.449; 95% CI = 2.137–51.088, P = 0.004) were the independent characteristics of patients with delayed defervescence by multivariate analysis (Table 4).
DISCUSSION
Acute Q fever, scrub typhus, and murine typhus are the most common rickettsioses in Taiwan.5–9 Because the methods for definitive diagnosis of them are either laborious tasks or time-consuming and are available only in research laboratories, clinicians often empirically prescribe doxycycline as preemptive treatment of suspected patients. Thus, cases with delayed defervescence would be troublesome for clinicians. The results of this study suggested that in treating acute Q fever, scrub typhus, and murine typhus with doxycycline, clinicians should be aware that delayed defervescence may occur in patients presenting with jaundice, relative bradycardia, and absence of headache. Administration of appropriate antibiotics (keep doxycycline or use alternative antibiotics, which are also effective for these diseases) should not be influenced by the response to treatment in such patients.
Poor response to doxycycline may be resulting from infections of doxycycline-resistant or particularly virulent strains of the organisms, inadequate doxycycline concentrations in infection sites, more severe diseases, and factors of infected hosts. For scrub typhus, poor response to doxycycline treatment resulting from infections with doxycycline-resistant strains of O. tsutsugamushi has been reported in northern Thailand.10 For acute Q fever, the slow regression of symptoms despite appropriate antibiotic treatment has been mentioned, especially in patients with an erythrocyte sedimentation rate (ESR) of > 100/h, a high level of autoantibodies, and hepatitis.4,11 For such patients, a combination of steroids with appropriate antibiotic therapy has been suggested.4,11 Furthermore, doxycycline-resistant strains of C. burnetii may be one of the possible causes of poor clinical response.12,13 For murine typhus, doxycycline-resistant strains or those with poor response to doxycycline have not been reported in literature. In this study, two cases of murine typhus had delayed defervescence occurring on the 4th and 6th day of doxycycline treatment, respectively. However, the ESR level and autoantibodies are not routine examinations and could not be evaluated in this study. The identification of drug-resistant strains of these organisms can be performed only in highly technical research laboratories and measurement of doxycycline concentrations is not available in general hospitals. Both of them are not applicable in clinical practice.
Relative bradycardia (OR = 10.449; 95% CI = 2.137–51.088, P = 0.004), jaundice (OR = 6.242; 95% CI = 1.374–28.365, P = 0.018), and absence of headache (OR = 8.310; 95% CI = 1.990–34.706, P = 0.004) are the independent characteristics of patients with delayed defervescence in this study (Table 4). The exact mechanism of relative bradycardia is not well understood. The mechanism of febrile response during infection is a complex process that includes interactions between exogenous pyogenes, such as exotoxin and endotoxins released from pathogens, and endogenous pyogenes, such as cytokines, tumor necrosis factors-α(TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferons released from cells of infected hosts.14 In addition to the induction of fever, TNF-α, IL-1, and IL-6 are inversely associated with vagal activity.15,16 Vagal stimulation can significantly attenuate the release of TNF-α, IL-1, and IL-6.17 Thus, the possible mechanism for the relative bradycardia may be as follows: infection causes the release of cytokines (TNF-α, IL-1, and IL-6) that induce fever at the level of the thermoregulation center, whereas the activated vagal response to modulate the release of cytokines also affects cardiac rhythm simultaneously. To the best of our knowledge, the association between relative bradycardia and protracted pyrexia in infectious diseases had never been reported. We hypothesize that patients with delayed defervescence to doxycycline treatment may have higher vagal response to modulate the released cytokines because of individual host factors that results in the significantly higher percentage of relative bradycardia in them. However, the clear mechanism of relative bradycardia and our hypothesis demand further investigation.
Liver involvement in acute Q fever, scrub typhus, and murine typhus is not uncommon, and the clinical manifestations include elevation of liver enzymes (hepatitis), hepatomegaly, and jaundice. For acute Q fever, pneumonia and hepatitis are the two major clinical presentations,4 and the latter is predominant in Taiwan.5,6,18,19 About 23–50% patients of acute Q fever have hepatomegaly.5,6,20–23 For scrub typhus, abnormal liver function is rarely mentioned in Western literature, but it is common in reports from Vietnam,24 Japan,25 and Taiwan26,27 and about 30% of patients have an enlarged spleen and liver.28 For murine typhus, 65–90% of patients have elevated liver enzymes29–31 and hepatomegaly is found in 24% of patients in one study from Thailand.31 Jaundice is found in 4.5–20%,4–6 1–44.7%,6,24,26,27 and 3–11%30,31 of cases of acute Q fever, scrub typhus, and murine typhus, respectively. However, only jaundice was significantly predominant in patients with delayed defervescence both by univariate and multivariate analysis (Tables 1 and 4). The lack of significant difference in serum total bilirubin level > 1.5 mg/dL between the two groups might be resulting from the small numbers of tested cases (59/108, 55.7%), because most clinicians would not examine serum bilirubin levels if jaundice was not clinically obvious. Other hepatic organic abnormalities that may cause hyperbilirubinemia, such as biliary tract obstruction or hepatic lesion, were not found in our cases. Furthermore, the percentage of underlying hepatitis virus infections or cirrhosis was not different between the two groups (Table 1). Thus, the presence of jaundice rather than levels of elevated liver enzymes or hepatomegaly may represent a more severe liver involvement in acute Q fever, scrub typhus, and murine typhus and results in delayed defervescence despite doxycycline treatment.
Although headache is a common symptom in rickettsioses and suggests central nervous system (CNS) involvement,32 whether its presence or not is associated with delayed defervescence despite adequate antibiotic treatment has never been reported. CNS involvement with the presentations of meningitis and meningoencephalitis has been reported in Q fever,33,34 scrub typhus,35,36 and murine typhus.36,37 The exact mechanism of CNS involvement in acute Q fever, scrub typhus, and murine typhus has not been well established. Vasculitis presenting as inflammatory cell infiltration over the peri-vascular spaces of CNS capillaries have been found in scrub typhus and murine typhus.35–37 In contrast, in one necropsy findings of a patient who died of Q fever, no peri-vascular infiltration was found despite the existence of capillary endothelial swelling and organisms found inside and outside the endothelial and neuroglial cells.38 It can be expected that patients with CNS involvement represents a more severe disease and results in poorer response to treatment. However, absence of headache is predominant in patients with delayed defervescence both by univariate and multivariate analysis in our study (Tables 1 and 4). It is possible that patients without headache have delayed diagnosis and treatment compared with those with headache, thereby resulting in poorer response to doxycycline treatment. However, the mean days from disease onset to hospital visit and days from disease onset to doxycycline treatment were not different between the two groups (P > 0.05; Tables 1–3). No deterioration of consciousness or focal neurologic signs was found in our patients. However, the headache was severe enough to prompt lumbar puncture in four patients (1 Q fever, 2 scrub typhus, and 1 murine typhus) to rule out meningitis, and they were all cases without delayed defervescence after doxycycline treatment. Thus, the association of absence of headache with delayed defervescence despite doxycycline treatment in acute Q fever, scrub typhus, and murine typhus demands further investigation.
In addition to the clinical characteristics, the possible influence of differences in duration from disease onset to hospital visit, to various examinations, and to initiation of doxycycline treatment between the two groups were excluded in our study because the differences were not statistically significant (P > 0.05; Tables 1–3).
Although the characteristics of acute Q fever, scrub typhus, and murine typhus with delayed defervescence after treatment of doxycycline are identified in our study, they should be applied carefully in clinical. The possibility of misdiagnosis should be kept in mind and further investigation of infections caused by other pathogens should be considered.
Our study has certain limitations. This is a hospital-based retrospective study and the potential bias of including more severe cases may exist. The number of studied cases is small (18 cases with delayed defervescence and 88 cases without delayed defervescence), which may limit the interpretative power of the results. The mechanisms of delayed defervescence despite doxycycline in acute Q fever, scrub typhus, and murine typhus might be different, and it could not be uncovered in this study because the three diseases are included in one study group. Whether infection of doxycycline-resistant strains or failure to reach a minimal inhibitory concentration (MIC) level of doxycycline in serum is one of the causes of delayed defervescence demands further investigation.
In summary, acute Q fever, scrub typhus, and murine typhus with delayed defervescence despite doxycycline treatment are troublesome for clinicians to diagnose and treat. Absence of headache, relative bradycardia, and jaundice are independent characteristics for a patient with delayed defervescence. In addition to infections from doxycycline-resistant or particularly virulent strains of the organisms and more severe diseases, other causes that may produce a poor response to doxycycline treatment, such as factors of infected hosts, require further investigation.
Demographic data, symptoms and signs of acute Q fever, scrub typhus, and murine typhus cases with and without delayed defervescence after doxycycline treatment
| 18 cases with delayed defervescence, n (%) | 88 cases without delayed defervescence, n (%) | P* | |
|---|---|---|---|
| * Categorical variables are analyzed using the χ2 or Fisher’s exact test as appropriate. Continuous variables are analyzed using the Student’s t test. | |||
| † Presented as mean value ± standard deviation. | |||
| ‡ Confirmed by examinations of HBsAg and anti-HCV. | |||
| ¶ Confirmed by abdominal ultrasonography or computed tomography. | |||
| || Body temperature ≥38.9°C and heart rate < 110/min without medication with calcium blockers, beta-blockers, or anti-arrhythmic agents | |||
| Diseases | |||
| Acute Q fever | 9 (50.0) | 52 (59.1) | 0.477 |
| Scrub typhus | 7 (38.9) | 31 (35.2) | 0.768 |
| Murine typhus | 2 (11.1) | 5 (5.7) | 0.339 |
| Demographic characteristics | |||
| Mean days from disease onset to hospital visit† | 5.6 ± 3.3 | 5.8 ± 3.3 | 0.850 |
| Sex, male/female | 17/1 (94.4/5.6) | 69/19 (78.4/21.6) | 0.185 |
| Age, mean (years)† | 45.4 ± 11.8 | 43.8 ± 14.5 | 0.645 |
| Alcoholism | 1 (5.6) | 5 (5.7) | 0.999 |
| Hepatitis B or C virus infection‡ | 4/18 (22.2) | 22/85 (25.9) | 0.999 |
| Hepatitis B virus | 4/18 (22.2) | 13/85 (15.3) | 0.491 |
| Hepatitis C virus | 0/18 (0) | 9/85 (10.6) | 0.354 |
| Liver cirrhosis¶ | 1/18 (5.6) | 2/81 (2.5) | 0.456 |
| Hypertension | 3 (16.7) | 10 (11.4) | 0.460 |
| Diabetes mellitus | 1 (5.6) | 6 (6.8) | 0.999 |
| Congestive heart failure | 0 (0) | 1 (1.1) | 0.999 |
| Chronic obstructive pulmonary disease | 0 (0) | 2 (2.3) | 0.999 |
| Malignancy | 0 (0) | 1 (1.1) | 0.999 |
| Symptoms | |||
| Fever | 18 (100) | 88 (100) | NC |
| Chills | 16 (88.9) | 67 (76.1) | 0.350 |
| Absence of headache | 7 (38.9) | 8 (9.1) | 0.004 |
| Sore throat | 1 (5.6) | 8 (9.1) | 0.999 |
| Cough | 10 (55.6) | 31 (35.2) | 0.107 |
| Jaundice | 5 (27.8) | 7 (8.0) | 0.030 |
| Diarrhea | 3 (16.7) | 8 (9.1) | 0.393 |
| Abdominal pain/discomfort | 2 (11.1) | 13 (14.8) | 0.999 |
| Nausea/vomiting | 1 (5.6) | 9 (10.2) | 0.999 |
| Arthralgia | 0 (0) | 5 (5.7) | 0.586 |
| Myalgia | 5 (27.8) | 25 (28.4) | 0.957 |
| General weakness | 1 (5.6) | 10 (11.4) | 0.686 |
| Signs | |||
| Skin rash | 3 (16.7) | 15 (17.0) | 0.999 |
| Eschar | 1 (5.6) | 7 (8.0) | 0.999 |
| Icteric sclera | 5 (27.8) | 7 (8.0) | 0.030 |
| Lymphadenopathy | 0 (0) | 7 (8.0) | 0.600 |
| Relative bradycardia|| | 15 (83.3) | 39 (44.3) | 0.003 |
Laboratory examinations and image findings of acute Q fever, scrub typhus, and murine typhus cases with and without delayed defervescence after doxycycline treatment
| 18 cases with delayed defervescence, n (%) | 88 cases without delayed defervescence, n (%) | P* | |
|---|---|---|---|
| * Categorical variables are analyzed using the χ2 or Fisher’s exact test as appropriate. Continuous variables are analyzed using the Student’s t test. | |||
| † Presented as mean value ± standard deviation. | |||
| Leukocytosis = white blood cell count > 10,000/mm3; leukopenia = white blood cell count < 4,000/mm3; lymphopenia = lymphocyte count < 1,000/mm3; monocytosis = monocyte count > 800/mm3; anemia = hemoglobin < 10 g/dL; ALT = alanine aminotransferase; AST = aspartate aminotransferase. | |||
| Blood cell examination | |||
| Days from disease onset to examinations† | 5.8 ± 3.1 | 5.6 ± 3.4 | 0.798 |
| Leukocytosis | 2 (11.1) | 5 (5.7) | 0.339 |
| Leukopenia | 1 (5.6) | 13 (14.8) | 0.456 |
| Lymphopenia | 9 (50.0) | 33 (37.5) | 0.323 |
| Monocytosis | 2 (11.1) | 7 (8.0) | 0.648 |
| Anemia | 1 (5.6) | 1 (1.1) | 0.312 |
| Platelet count < 150,000/mm3 | 11 (61.1) | 64 (72.7) | 0.324 |
| Platelet count < 100,000/mm3 | 6 (33.3) | 18 (20.5) | 0.233 |
| Biochemical examination | |||
| Days from disease onset to examinations† | 5.8 ± 3.1 | 5.8 ± 3.2 | 0.994 |
| Creatinine > 2.0 mg/dL | 2/17 (11.8) | 1/82 (1.2) | 0.075 |
| ALT > 44 U/L | 17/18 (94.4) | 79/87 (90.8) | 0.999 |
| ALT > 88 U/L | 10/18 (55.6) | 56/87 (64.4) | 0.481 |
| AST > 38 U/L | 18/18 (100) | 83/88 (94.3) | 0.586 |
| AST > 76 U/L | 11/18 (61.1) | 65/88 (73.9) | 0.274 |
| ALT level (U/L)† | 114.9 ± 60.9 | 135.2 ± 97.2 | 0.398 |
| AST level (U/L)† | 114.5 ± 53.6 | 127.9 ± 103.0 | 0.592 |
| Total bilirubin > 1.5 mg/dL | 6/12 (50.0) | 12/47 (25.5) | 0.158 |
| Chest x-ray (CXR) | 18/18 (100) | 87/88 (98.9) | 0.999 |
| Days from disease onset to CXR† | 5.6 ± 3.3 | 5.7 ± 3.3 | 0.885 |
| Pulmonary involvement on CXR | 10/18 (55.6) | 25/87 (28.7) | 0.028 |
| Unilateral infiltration | 3/18 (16.7) | 11/87 (12.6) | 0.704 |
| Bilateral infiltration | 7/18 (38.9) | 14/87 (16.1) | 0.047 |
| Consolidation | 0 (0) | 0 (0) | NC |
| Abdominal ultrasonography or computerized tomograpgy (CT) | 18/18 (100) | 81/88 (92.0) | 0.600 |
| Days from disease onset to abdominal ultrasonography or CT† | 7.7 ± 3.4 | 6.9 ± 3.9 | 0.415 |
| Cholecystitic change | 5/18 (27.8) | 17/81 (21.0) | 0.540 |
| Gallbladder wall thickening | 3/18 (16.7) | 15/81 (18.5) | 0.999 |
| Gallbladder distention | 2/18 (11.1) | 2/81 (2.5) | 0.150 |
| Hepatomegaly or splenomegaly | 9/18 (50.0) | 30/81 (37.0) | 0.309 |
| Hepatomegaly | 5/18 (27.8) | 18/81 (22.2) | 0.758 |
| Splenomegaly | 7/18 (38.9) | 20/81 (24.7) | 0.249 |
| Fatty liver | 12/18 (66.7) | 38/81 (46.9) | 0.129 |
| Cirrhotic change | 1/18 (5.6) | 2/81 (2.5) | 0.456 |
Duration from disease onset to doxycycline treatment of acute Q fever, scrub typhus, and murine typhus cases with and without delayed defervescence after treatment
| 18 cases with delayed defervescence, n (%) | 88 cases without delayed defervescence, n (%) | P* | |
|---|---|---|---|
| * Categorical variables are analyzed using the χ2 or Fisher’s exact test as appropriate. Continuous variables are analyzed using the Student’s t test. | |||
| † Presented as mean value ± standard deviation | |||
| Days from disease onset to doxycycline treatment† | 7.1 ± 4.1 | 6.5 ± 3.4 | 0.531 |
| Duration from disease onset to doxycycline treatment | |||
| > 7 days | 7 (38.5) | 24 (27.3) | 0.324 |
| > 10 days | 3 (16.7) | 7 (8.0) | 0.368 |
| > 14 days | 1 (5.6) | 4 (4.5) | 0.999 |
Multivariate analysis of characteristics of acute Q fever, scrub typhus, and murine typhus cases with delayed defervescence after doxycycline treatment
| Characteristics | Odds ratio (95% CI) | P |
|---|---|---|
| * Body temperature ≥ 38.9°C and heart rate < 110/min without medication with calcium blockers, beta-blockers, or anti-arrhythmic agents. | ||
| CI = confidence interval; CXR = chest x-ray. | ||
| Absence of headache | 8.310 (1.990–34.706) | 0.004 |
| Jaundice | 6.242 (1.374–28.365) | 0.018 |
| Relative bradycardia* | 10.449 (2.137–51.088) | 0.004 |
| Pulmonary involvement on CXR | 2.147 (0.634–7.276) | 0.220 |
Percentage of fever in patients with and without delayed defervescence after doxycycline treatment.
Citation: The American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg 79, 3; 10.4269/ajtmh.2008.79.441
Percentage of fever in patients with and without delayed defervescence after doxycycline treatment.
Citation: The American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg 79, 3; 10.4269/ajtmh.2008.79.441
Percentage of fever in patients with and without delayed defervescence after doxycycline treatment.
Citation: The American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg 79, 3; 10.4269/ajtmh.2008.79.441
Address correspondence to Hsi-Hsun Lin, Section of Infectious Diseases, Department of Internal Medicine, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China. E-mail: ed100233@yahoo.com.tw
Authors’ addresses: Chung-Hsu Lai, Section of Infectious Disease, Department of Internal Medicine, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China, Tel: 886-7-615-0011-5558, Fax: 886-7-615-0960, E-mail: laich6363@yahoo.com.tw. Chun-Kai Huang, Section of Infectious Disease, Department of Internal Medicine, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China, Tel: 886-7-615-0011-5555, Fax: 886-7-615-0960, E-mail: ed103536@edah.org.tw. Hui-Ching Weng, Department of Health Management, I-Shou University, 8 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan Kaohsiung County, Taiwan, Republic of China, Tel: 886-7-615-1100-7420, Fax: 886-7-615-0960, E-mail: weng@mail.isu.edu.tw. Hsing-Chun Chung, Section of Infectious Disease, Department of Internal Medicine, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China, Tel: 886-7-615-0011-5556, Fax: 886-7-615-0960, E-mail: ed102749@edah.org.tw. Shiou-Haur Liang, Section of Infectious Disease, Department of Internal Medicine, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China, Tel: 886-7-615-0011-5554, Fax: 886-7-615-0960, E-mail: ed103519@edah.org.tw. Jiun-Nong Lin, Section of Infectious Disease, Department of Internal Medicine, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China, Tel: 886-7-615-0011-5557, Fax: 886-7-615-0960, E-mail: ed103623@edah.org.tw. Chih-Wen Lin and Chuan-Yuan Hsu, Section of Gastroenterology, Department of Internal Medicine, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China, Tel: 886-7-615-0011, Fax: 886-7-615-0960, E-mails: ed101968@edah.org.tw and ed101800@edah.org.tw. Hsi-Hsun Lin, Department of Infectious Disease, E-Da Hospital/I-Shou University, 1 E-Da Road, Jiau-Shu Tsuen, Yan-Chau Shiang, Kaohsiung County, 824 Taiwan, Republic of China, Tel: 886-7-615-0011-5550, Fax: 886-7-615-0960, E-mail: ed100233@yahoo.org.tw.
Financial support. This study was partially supported by a research grant from E-Da Hospital (EDAH-D-97(P)007A).
Disclaimer: All authors have no conflict of interest.
REFERENCES
- 1↑
Raoult D, Roux V, 1997. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev 10 :694–719.
- 2↑
Botelho-Nevers E, Raoult D, 2007. Fever of unknown origin due to rickettsioses. Infect Dis Clin North Am 21 :997–1011.
- 3↑
La Scola B, Raoult D, 1997. Laboratory diagnosis of rickettsioses: current approaches to diagnosis of old and new rickettsial diseases. J Clin Microbiol 35 :2715–2727.
- 5↑
Lai CH, Huang CK, Chin C, Chung HC, Huang WS, Lin CW, Hsu CY, Lin HH, 2008. Acute Q fever: an emerging and endemic disease in southern Taiwan. Scand J Infect Dis 40 :105–110.
- 6↑
Lee HC, Ko WC, Lee HL, Chen HY, 2002. Clinical manifestations and complications of rickettsiosis in southern Taiwan. J Formos Med Assoc 101 :385–392.
- 7
Lee YS, Wang PH, Tseng SJ, Ko CF, Teng HJ, 2006. Epidemiology of scrub typhus in eastern Taiwan, 2000–2004. Jpn J Infect Dis 59 :235–238.
- 8↑
Chen HL, Chen HY, Wu YC, Horng CB, 1994. Q fever in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 54 :1–6.
- 9↑
Chen HL, Chen HY, Horng CB, 1993. Surveillance of scrub typhus in Taiwan. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 26 :166–170.
- 10↑
Watt G, Chouriyagune C, Ruangweerayud R, Watcharapichat P, Phulsuksombati D, Jongsakul K, Teja-Isavadharm P, Bhodhidatta D, Corcoran KD, Dasch GA, Strickman D, 1996. Scrub typhus infections poorly responsive to antibiotics in northern Thailand. Lancet 348 :86–89.
- 12↑
Rolain JM, Lambert F, Raoult D, 2005. Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline. Ann NY Acad Sci 1063 :252–256.
- 13↑
Rolain JM, Boulos A, Mallet MN, Raoult D, 2005. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 49 :2673–2676.
- 14↑
Netea MG, Kullberg BJ, Van der Meer JW, 2000. Circulating cytokines as mediators of fever. Clin Infect Dis 31 (Suppl 5):S178–S184.
- 15↑
Marsland AL, Gianaros PJ, Prather AA, Jennings JR, Neumann SA, Manuck SB, 2007. Stimulated production of proinflammatory cytokines covaries inversely with heart rate variability. Psychosom Med 69 :709–716.
- 16↑
Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T, 2007. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 13 :178–184.
- 17↑
Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ, 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 :458–462.
- 18↑
Lai CH, Chin C, Chung HC, Huang CK, Chen WF, Yang YT, Chen W, Lin HH, 2007. Acute Q fever hepatitis in patients with and without underlying hepatitis B or C virus infection. Clin Infect Dis 45 :e52–e59.
- 19↑
Chang K, Yan JJ, Lee HC, Liu KH, Lee NY, Ko WC, 2004. Acute hepatitis with or without jaundice: a predominant presentation of acute Q fever in southern Taiwan. J Microbiol Immunol Infect 37 :103–108.
- 20↑
Luksic B, Punda-Polic V, Ivic I, Bradaric I, Bradaric N, 2006. Clinical and epidemiological features of hospitalized acute Q fever cases from Split-Dalmatia County (Croatia), 1985–2002. Med Sci Monit 12 :CR126–CR131.
- 21
Alarcon A, Villanueva JL, Viciana P, Lopez-Cortes L, Torronteras R, Bernabeu M, Cordero E, Pachon J, 2003. Q fever: epidemiology, clinical features and prognosis. A study from 1983 to 1999 in the South of Spain. J Infect 47 :110–116.
- 22
Ergas D, Keysari A, Edelstein V, Sthoeger ZM, 2006. Acute Q fever in Israel: clinical and laboratory study of 100 hospitalized patients. Isr Med Assoc J 8 :337–341.
- 23↑
Sampere M, Font B, Font J, Sanfeliu I, Segura F, 2003. Q fever in adults: review of 66 clinical cases. Eur J Clin Microbiol Infect Dis 22 :108–110.
- 24↑
Berman SJ, Kundin WD, 1973. Scrub typhus in South Vietnam. A study of 87 cases. Ann Intern Med 79 :26–30.
- 25↑
Ogawa M, Hagiwara T, Kishimoto T, Shiga S, Yoshida Y, Furuya Y, Kaiho I, Ito T, Nemoto H, Yamamoto N, Masukawa K, 2002. Scrub typhus in Japan: epidemiology and clinical features of cases reported in 1998. Am J Trop Med Hyg 67 :162–165.
- 26↑
Hu ML, Liu JW, Wu KL, Lu SN, Chiou SS, Kuo CH, Chuah SK, Wang JH, Hu TH, Chiu KW, Lee CM, Changchien CS, 2005. Short report: abnormal liver function in scrub typhus. Am J Trop Med Hyg 73 :667–668.
- 27↑
Yang CH, Hsu GJ, Peng MY, Young TG, 1995. Hepatic dysfunction in scrub typhus. J Formos Med Assoc 94 :101–105.
- 28↑
Seong SY, Choi MS, Kim IS, 2001. Orientia tsutsugamushi infection: overview and immune responses. Microbes Infect 3 :11–21.
- 29↑
Bernabeu-Wittel M, Pachon J, Alarcon A, Lopez-Cortes LF, Viciana P, Jimenez-Mejias ME, Villanueva JL, Torronteras R, Caballero-Granado FJ, 1999. Murine typhus as a common cause of fever of intermediate duration: a 17-year study in the south of Spain. Arch Intern Med 159 :872–876.
- 30↑
Dumler JS, Taylor JP, Walker DH, 1991. Clinical and laboratory features of murine typhus in south Texas, 1980 through 1987. JAMA 266 :1365–1370.
- 31↑
Silpapojakul K, Mitarnun W, Ovartlarnporn B, Chamroonkul N, Khow-Ean U, 1996. Liver involvement in murine typhus. QJM 89 :623–629.
- 32↑
Bleck TP, 1999. Central nervous system involvement in Rickettsial diseases. Neurol Clin 17 :801–812.
- 33↑
Bernit E, Pouget J, Janbon F, Dutronc H, Martinez P, Brouqui P, Raoult D, 2002. Neurological involvement in acute Q fever: a report of 29 cases and review of the literature. Arch Intern Med 162 :693–700.
- 34↑
Kofteridis DP, Mazokopakis EE, Tselentis Y, Gikas A, 2004. Neurological complications of acute Q fever infection. Eur J Epidemiol 19 :1051–1054.
- 35↑
Pai H, Sohn S, Seong Y, Kee S, Chang WH, Choe KW, 1997. Central nervous system involvement in patients with scrub typhus. Clin Infect Dis 24 :436–440.
- 36↑
Silpapojakul K, Ukkachoke C, Krisanapan S, Silpapojakul K, 1991. Rickettsial meningitis and encephalitis. Arch Intern Med 151 :1753–1757.
- 37↑
Masalha R, Merkin-Zaborsky H, Matar M, Zirkin HJ, Wirguin I, Herishanu YO, 1998. Murine typhus presenting as subacute meningoencephalitis. J Neurol 245 :665–668.